Medicine for relieving inflammatory aging induced by inflammatory pathogenic bacteria
By developing the Lsd1 inhibitor GSK2879552, the problem of inflammatory aging induces inflammatory caused by targeted epigenetic regulatory changes was solved, which significantly delayed aging and extended the lifespan of mice, filling the gap in the existing technology.
Patent Information
- Application Number
- CN202410949697.0
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-07-16
- Publication Date
- 2024-11-22
AI Technical Summary
The prior art is difficult to effectively solve the problem of aging caused by targeted epigenetic regulatory changes, especially inflammatory aging induced by inflammatory pathogenic bacteria.
GSK2879552, an inhibitor of specific demethylase Lsd1, was developed as an inhibitor of histone H3K4me3 modification, regulates the level of H3K4me3 modification, reduces heterochromatinization, and relieves and reverses premature aging and natural aging caused by inflammation.
It significantly prolongs the survival rate of inflammatory and naturally aged mice, delays aging, and extends lifespan, filling the gap in aging drugs caused by targeted epigenetic regulatory changes.
Smart Images

Figure CN118986980A_ABST
Abstract
Description
Technical Field
[0001] The present invention belongs to the field of development of anti-aging related drugs, and specifically relates to a drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria. Background Art
[0002] As a biological phenomenon, aging is a series of irreversible organ function degeneration and death that accompanies the increase of individual life span, and its direct manifestation is the length of individual life span. Various diseases induced by aging are also closely related to the quality of life of individuals. Therefore, delaying aging is of great significance in prolonging life, slowing down the degenerative diseases associated with aging, improving the quality of life of the elderly, and reducing the burden on families and society.
[0003] The cell biological mechanisms that lead to the acceleration of the aging process involve complex regulatory changes, such as genetic mutations, changes in epigenetic regulation, metabolic abnormalities, signal transduction disorders, stem cell depletion, energy supply imbalance, etc. The consequences of the cumulative effects of multiple effects lead to reduced or lost cell viability, which in turn causes an aging phenotype characterized by decreased tissue function. Focusing on the different causes of aging, scientists have conducted a series of targeted studies, hoping to find interventions to delay aging and make some important progress. For example, in response to the accelerated aging caused by abnormal metabolism of the body, researchers have found that through "calorie restriction", controlling daily calorie intake and reducing the effects of abnormal glucose metabolism can achieve the purpose of extending life or delaying aging. Using the hypoglycemic drug metformin to intervene in the body's glucose metabolism in advance can also show the effect of extending life similar to that achieved by calorie control. In addition, NAD (nicotinamide adenine dinucleotide) has been found to be another star molecule that can significantly delay the aging of the body. NAD mainly targets the abnormalities of mitochondrial function and energy metabolism in aging tissues. Supplementing NAD can increase the substrate of mitochondrial energy metabolism to restore vitality. In addition, NAD, as a coenzyme of the longevity gene Sirt2, can also improve the body's anti-aging ability by increasing the activity of Sirt2. In view of the risk of accelerated aging caused by genetic changes, the factors that induce genetic instability can be reduced as much as possible. For example, increasing the antioxidant capacity of cells can effectively reduce the genetic changes caused by the accumulation of reactive oxygen. Vitamin C, resveratrol, quercetin, etc. all show a certain degree of anti-aging effect due to their strong antioxidant activity; on the other hand, for mutated cells, researchers can also use gene editing to correct genetically mutated DNA to reduce the risk of aging caused by genetic mutations, but the technical accuracy of gene editing still needs to be further improved. In view of the fact that the accumulation of senescent cells hinders the body's regenerative ability, researchers have developed a variety of senescent cell scavengers senolytics to induce the hope of accelerating the death of senescent cells, thereby improving the regeneration and repair ability of body tissues. Summary of the invention
[0004] In view of the lack of targeted epigenetic regulatory changes in the prior art to address the aging problem, the present invention provides a drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria.
[0005] The drug is a specific inhibitor of the demethylase Lsd1.
[0006] Furthermore, the drug is histone H3K4me3 modified.
[0007] Furthermore, the drug inhibits the trend of increased heterochromatinization induced by inflammatory aging and natural aging, and alleviates and reverses inflammatory premature aging and natural aging caused by inflammation.
[0008] Furthermore, the drug is GSK2879552.
[0009] The drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria provided by the present invention can significantly prolong the survival rate of naturally aged and inflammatory aged mice, showing a significant effect of delaying aging and prolonging life span, and fills the gap of drugs targeting aging caused by changes in epigenetic regulation. BRIEF DESCRIPTION OF THE DRAWINGS
[0010] Figure 1 :Schematic diagram of the establishment of an inflammatory aging model in mice infected with pathogenic bacteria PA14 and the RNA transcription level of inflammatory factors.
[0011] Figure 2 : Schematic diagram of mice treated with small molecule inhibitors.
[0012] Figure 3 :Schematic diagram of how GSK2879552 small molecule inhibitor alleviates the body weight of inflammatory aging mice.
[0013] Figure 4 :Schematic diagram of how the GSK28789552 small molecule inhibitor extends the lifespan of aged mice. DETAILED DESCRIPTION
[0014] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and understandable, the specific implementation modes of the present invention are described in detail below with reference to the accompanying drawings, but they should not be construed as limiting the applicable scope of the present invention.
[0015] Abnormal changes in epigenetic regulation are considered to be the most critical cause of inducing natural aging and premature aging of individual cells. The present invention provides a drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria, targeting the epigenetic regulatory network, alleviating or reversing inflammatory aging and natural aging. The drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria provided by the present invention increases the level of H3K4me3 by inhibiting the action of Lsd1, inhibits the trend of increased heterochromatinization induced by inflammatory aging and natural aging, and alleviates and reverses inflammatory premature aging and natural aging caused by inflammation.
[0016] In one embodiment, the drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria is GSK2879552. 23 H 28 N2O2·2HCl) is a specific inhibitor of the specific demethylase Lsd1 of histone H3K4me3 modification, and H3K4me3 modification is a characteristic of the promoter region of the transcriptional activation gene region, which helps to maintain the open euchromatin state, thereby facilitating gene transcription. By regulating the activity of Lsd1, the level of euchromatin can be reduced by reducing H3K4me3 modification, changing the balance of dynamic antagonism between euchromatin and heterochromatin, for example, by euchromatinization of genes, the transcriptional expression of inactivated genes is increased to maintain the normal vitality and function of cells. At present, GSK2879552 is used in basic research related to tumor treatment.
[0017] Experiment 1 Construction and study of inflammation mouse model
[0018] PA14 is a conditional pathogen in humans and can induce inflammatory responses in mice. Mice were treated with oral gavage and nasal drops for 5 consecutive days to establish an intestinal and respiratory inflammation model. The results showed that PA14 induced high expression of inflammatory factors TNF-α, IL-6 and IL-1, accompanied by a rapid decrease in the weight of mice ( Figure 1 ). The intestinal stem cells of mice with inflammation were analyzed and the results showed that the number of intestinal stem cells was significantly reduced in mice treated with PA14.
[0019] Pseudomonas aeruginosa PA14, a conditional pathogen of humans, is a Gram-negative bacterium with special virulence-related genes and drug resistance. This strain causes infection and poses a greater threat to patients with impaired immune systems. Infection with PA14 can cause inflammatory responses in mouse tissues. The general practice is to inject PA14 into mice to simulate infection and inflammatory responses. The present invention uses a combination of oral gavage and nasal drops to colonize a certain concentration of PA14 into the digestive system such as the gastrointestinal tract and the respiratory system such as the lungs and bronchi. The concentration of the bacteria used for oral gavage is 5x 10 6 CFU, the concentration of bacteria used in nasal drops is 1x 10 6CFU. The specific method is as follows: centrifuge the PA14 bacteria cultured overnight, collect the precipitate; dilute with saline and determine the CFU. Take 5-month-old mice, use a gavage needle to draw PA14 (dissolved in saline) for gavage; after gavage, anesthetize the mice, use a gun to inhale the PA14 bacterial solution (dissolved in saline), drip it into the mouse's nostrils, and wait for the mouse to inhale the bacterial solution through breathing. Give the mice PA14 gavage and nasal drops every day, for a total of 5-7 days, and weigh and record the weight of the mice.
[0020] After 7 days of PA14 treatment, the intestines and lungs of mice were dissected. Part of the intestinal and lung tissues were taken, ground, lysed, RNA was extracted, reverse transcribed to synthesize cDNA, and QPCR was used to detect the expression levels of some inflammatory factors TNF-α, IL-6, and IL-1.
[0021] After 7 days of PA14 treatment, the intestines and lungs of mice were dissected, embedded in paraffin, and sectioned. Immunofluorescence staining was used to observe the intestinal stem cell marker OFLM4, and the proportion of positive cells to the total intestinal cells was calculated.
[0022] The results of the mouse inflammatory aging model are shown in Figure 1 Wild-type female mice, 2 months old, were divided into a control group and an experimental group, with two mice in each group. The experimental group was intragastrically administered with PA14 (5 x 10 6 CFU, dissolved in saline) and nasal drops PA14 (1x 10 6 CFU, dissolved in physiological saline) and tissues were collected after 5-7 days (upper left). The control group was fed normally and tissues were collected after 5-7 days. After infection with PA14, the weight of mice in the experimental group decreased immediately (upper right), while the weight of the control group remained basically unchanged. The expression levels of inflammatory factors TNF-α, IL-6, and IL-1 detected by QPCR in the lungs of inflamed mice were increased compared with those in the control group (lower left). The expression levels of inflammatory factors TNF-α, IL-6, and IL-1 detected by QPCR in the intestines of inflamed mice were increased compared with those in the control group (lower right).
[0023] Experiment 2 Inflammatory premature aging mice and anti-aging treatment
[0024] Female mice survived about 4 months after PA14 treatment. In addition to weight loss, other phenotypes of premature aging were also seen, including hair changes and motor coordination disorders. In addition to the PA14 treatment group, a small molecule GSK2879552 control group was also set up. Mice were infected by oral gavage and nasal drops, and GSK2879552 (0.5 mg / kg) was injected into the tail vein every day. After 7 days of PA14 treatment, GSK2879552 (0.5 mg / kg) was changed to be injected once every 3 days for 6 consecutive months ( Figure 2 ), and the control group was injected with normal saline via the tail vein. The weight changes and survival of mice were detected during the 6-month continuous injection.
[0025] Figure 3 Schematic diagram of the GSK2879552 small molecule inhibitor alleviating the weight of inflammatory aging mice. PA14 infection alone caused a sharp drop in the weight of mice, and the maximum lifespan of female mice (left) ended at around 100 days; all mice treated with GSK2879552 were still alive and healthy after 180 days. The weight loss of mice treated with GSK2879552 was effectively alleviated, and the weight was similar to that of untreated mice in the control group. Male mice (right) had a significantly longer lifespan of inflammatory mice injected with the GSK2879552 drug compared to the PA14-treated control group mice.
[0026] Experiment 3: Lifespan study of naturally aged mice
[0027] 26-month-old naturally aged mice were injected with the small molecule drug GSK2879 (0.5 mg / kg) through the tail vein every 2-3 days, and the control group was injected with normal saline. The survival rates of the control group and the GSK2879 injection group (drug feeding group) were continuously observed and recorded. Figure 4 The life span of mice in the control group all ended at 100 days, while the life span of mice in the GSK2879-treated group was significantly extended. The median survival of mice in the control group was about 27 months, while the median survival of mice in the drug-fed group exceeded 31 months, an extension of about 15%. The body weight of the drug-fed group was generally higher than that of the control group.
[0028] The drug preparation composition of GSK2879522 is as follows: 5% GSK2879522 + 95% normal saline, and the drug control group is injected with DMSO (solvent of GSK2879522 drug), and the preparation composition is as follows: 5% DMSO + + 95% normal saline.
[0029] The drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria provided by the present invention can significantly prolong the survival rate of naturally aged and inflammatory aged mice, showing a significant effect of delaying aging and prolonging life span, and fills the gap of drugs targeting aging caused by changes in epigenetic regulation.
Claims
1. A drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria, characterized in that: The drug is a specific inhibitor of the demethylase Lsd1.
2. The drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria according to claim 1, characterized in that: The drug is histone H3K4me3 modified.
3. The drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria according to claim 1, characterized in that: The drug inhibits the trend of increased heterochromatinization induced by inflammatory aging and natural aging, and alleviates and reverses inflammatory premature aging and natural aging caused by inflammation.
4. The drug for alleviating inflammatory aging induced by inflammatory pathogenic bacteria according to claim 1, characterized in that: The drug is GSK2879552.
Citation Information
Cited By
Application of OICR-9429 or pharmaceutically acceptable salt thereof in preparation of products for improving aging indications
CN121648134A
